Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 94 | SFEBES2023 | Next issue

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Card image cap
SfE BES is the UK's leading endocrinology meeting. It will return to Glasgow in 2023.

Poster Presentations

Neuroendocrinology and Pituitary

ea0094p45 | Neuroendocrinology and Pituitary | SFEBES2023

Phaeochromocytoma/Paraganglioma – Call for Education and More Screening

Yung Zhuang Choo Alwyn , Ahluwalia Rupa , Joseph Neetha , Saada Janak , McArdle Nicholas , Chipchase Allison , Rochester Mark , Manson-Bahr David , Maxwell Melanie , Swe Myint Khin

Background: Phaeochromocytomas & paragangliomas (PPGL) are rare neuroendocrine tumours presenting with symptoms of sympathetic overactivity, hypertension, or as adrenal incidentalomas.Study and results: A 24-year retrospective review of a U.K. single-centre PPGL service (2009 -2023) identified 61 cases (53 phaeochromocytomas/8 paragangliomas). Among these, 35 (57%) were females. Mean age of diagnosis was 56.35±16....

ea0094p80 | Neuroendocrinology and Pituitary | SFEBES2023

Integrated multi-omics data reveals distinct regulatory signatures and signaling pathways of aryl hydrocarbon receptor interacting protein (AIP) knockout cells

Barry Sayka , Rai Ashutosh , Haworth Oliver , Rajeeve Vinothini , Cutillas Pedro , Korbonits Marta

Introduction: Aryl hydrocarbon receptor interacting protein (AIP) is a multifunctional co-chaperone protein with wide-ranging effects. It acts as a tumour suppressor in the pituitary, but may have other roles including oncogenic function in other tissues. To explore the molecular mechanisms, we have performed transcriptomic and phosphoproteomic analysis of Aip-knockout mouse embryonic fibroblasts (Aip-KO MEFs) cells and integrated these data sets.<p class=...

ea0094p81 | Neuroendocrinology and Pituitary | SFEBES2023

Osilodrostat: Effective and Safe Management of ACTH-Dependent Cushing’s Syndrome - A UK single centre experience

Htut Zin , Wernig Florian

We present three cases of ACTH-dependent Cushing’s syndrome, successfully managed with osilodrostat.Case 1: A 42-year-old woman diagnosed with ACTH-dependent Cushing’s disease was initially treated with osilodrostat dose-titration approach, as MRI of the pituitary did not identify a clear surgical target. By week five, serum cortisol levels fully normalised. Salivary and 24 hr urinary free cortisol (UFC) normalised on a mainten...

ea0094p82 | Neuroendocrinology and Pituitary | SFEBES2023

The effect of gamma knife radiosurgery on the endocrine profile in patients with non-sellar pathologies: A short-term study

Kaur Rupinder , Gurnaani Jenil , Rai Ashutosh , Dutta Pinaki , Kumar Narendra , K Ahuja Chirag , Chhabra Rajesh , Mohindra Sandeep , Tripathi Manjul

Introduction: Hypopituitarism is the most frequent side effect of radiation or gamma knife radiosurgery (GKRS) for sellar diseases. There is a paucity of literature on the impact of GKRS on the hormonal profile of non-sellar diseases, even though the impact of radiation on pituitary hormones has been widely explored in sellar as well as non-sellar pathologies. In patients receiving treatment for non-sellar diseases, we assessed the effect of GKRS on hormonal p...

ea0094p83 | Neuroendocrinology and Pituitary | SFEBES2023

The use of overnight fasting copeptin and glucagon stimulated copeptin to diagnose arginine vasopressin deficiency in a tertiary centre

Elamin Aisha , Munir Alia , Hussein Ziad

Introduction: Distinguishing arginine vasopressin deficiency (AVD) from primary polydipsia (PP) can be challenging in clinical practice. Copeptin is produced in equimolar amount to AV and is considered diagnostic biomarker to establish the diagnosis of AVD with and without provocative testing.Methods: Patients referred with polydipsia, hypotonic polyuria (>3L/day) and normonatraemia had overnight fasting plasma copep...

ea0094p84 | Neuroendocrinology and Pituitary | SFEBES2023

Prevalence of cancer in a cohort of patients with prolactinoma compared to acromegaly

Toma Iustin-Daniel , Trifanescu Raluca , Baciu Ionela , Baculescu Nicoleta , Burcea Iulia , Capatina Cristina , Dobre Ramona , Dusceac Roxana , Galoiu Simona , Niculescu Dan , Radian Serban , Poiana Catalina

Background: While growth hormone (GH) is involved in oncogenic transformation and IGF1 inhibits apoptosis, studies and case reports have shown an association between prolactin (PRL) and prostate cell proliferation, breast, gynecological, colorectal and hematopoietic cancer.Aim: To compare the cancer rates in prolactinomas vs. acromegaly.Methods: Retrospective study by analyzing the...

ea0094p85 | Neuroendocrinology and Pituitary | SFEBES2023

Development of an optimal imaging pathway for management of somatotroph tumors in acromegaly

Haberbosch Linus , Macfarlane James , Koulouri Olympia , Gillett Dan , Spranger Joachim , Mai Knut , Cheow Heok , Jones Jonathan , Strasburger Christian , Gurnell Mark

Background: Acromegaly is associated with significant excess morbidity and mortality. Surgery and radiotherapy (including radiosurgery) aim to reduce the burden of growth hormone excess while preserving normal pituitary function, but their effective deployment is dependent on high quality imaging that allows accurate localization of site(s) of active de novo or residual/recurrent disease. Despite the existence of several comprehensive guidelines on the managem...

ea0094p86 | Neuroendocrinology and Pituitary | SFEBES2023

Key predictors of quality of life in patients with acromegaly

Sorina Martin Carmen , Ioana Dorita Alina , Viorela Nacu Miruna , Elena Sirbu Anca , Gabriela Barbu Carmen , Fica Simona

Background: Despite current efforts in trying to accurately identify determinants of impaired quality of life (QoL) in acromegalic patients, studies on this topic are still conflicting and more research is needed in order to improve the well-being of these patients.Methods: We conducted a cross-sectional study, administering two standardized questionnaires (AcroQol and EuroQol-5D) to 38 acromegalic patients and examined ...

ea0094p87 | Neuroendocrinology and Pituitary | SFEBES2023

Pituitary apoplexy: a retrospective study of 71 cases from a single center

Ghenoiu Sandra , Sandu Andreea , Dumitrascu Anda , Alexandrescu Daniela , Capatina Cristina , Poiana Catalina

Background and objective: The purpose of this study was to retrospectively analyse the clinical, imaging and hormonal features, as well as the therapeutic outcomes in a series of consecutive patients presenting with pituitary apoplexy (PA).Design: We retrospectively reviewed 71 case-records of patients with PA admitted during 2019 in a single tertiary endocrinology center.Results: ...

ea0094p88 | Neuroendocrinology and Pituitary | SFEBES2023

Macroprolactin: Do we need to repeat its measurement?

Livingston Mark , Laing Ian , Heald Adrian

Macroprolactinaemia, a common phenomenon variably expressed in different assays, influences interpretation of prolactin results, as recognised since 1978. The degree of macroprolactinaemia manifest over time is less well described. We examined how macroprolactin status (based on polyethylene glycol(PEG) precipitation prolactin % recovery) varied over serial measurements in hyperprolactinaemic individuals.Methods: All serum total prolacti...

ea0094p89 | Neuroendocrinology and Pituitary | SFEBES2023

Desmopressin prescription safety in adult inpatients: Experience from a quality improvement project

Fahad Arshad Muhammad , Solanki Sam , Karunanayaka Madushani , Dancyger-Stevens Luka , Munir Alia

Background: Cranial Diabetes Insipidus (CDI) or Arginine-Vasopressin Deficiency (AVP-D) is a potentially life-threatening condition requiring treatment with desmopressin. Omission or delay in desmopressin can result in serious patient harm.Aims: Evaluation of desmopressin prescription/administration practice and implementation of an action plan to improve patient safety.Methods: Re...

ea0094p90 | Neuroendocrinology and Pituitary | SFEBES2023

Type 2 diabetes mellitus and the risk of parkinson’s disease; a systematic review and meta-analysis

Khalisah Shoaib , Bantounou Maria Anna , Adele Mazzoleni , Harsh Modalavalasa , Niraj Kumar , Sam Philip

Background: An estimated 462 million individuals are affected by type 2 diabetes mellitus (T2DM), corresponding to 6.28% of the world’s population. Many epidemiological studies have indicated that T2DM may be a risk factor for neurodegenerative diseases, including Parkinson’s disease (PD). Whilst research suggests there are common molecular mechanisms underlying the conditions, studies investigating the epidemiological association have revealed conflicting res...

ea0094p91 | Neuroendocrinology and Pituitary | SFEBES2023

A novel AIP deletion emphasising the variable phenotype of AIP-related pituitary neuroendocrine tumours

Benjamin Loughrey Paul , J Morrison Patrick , K Ellis Peter , R Mullan Karen , Korbonits Marta

A 16-year-old female presented with secondary amenorrhoea. Menarche was age 14 years and periods were less frequent over the preceding 12 months. There was no galactorrhoea, headache or visual field disturbance and no known family history of pituitary disease, tall stature or infertility. There were no clinical signs of Cushing’s disease or acromegaly and visual fields were full to confrontation. Height was 160 cm. Investigations showed a prolactin of 2,452 mIU/l (RR 102-...

ea0094p92 | Neuroendocrinology and Pituitary | SFEBES2023

A functioning gonadotroph macroadenoma presenting with features of OHSS and sustained remission 4-years after TSS

Khalilova Samira , Gonzales Christine , E Drakou Eftychia , K Dimitriadis Georgios

It is well established that the majority of the immunohistochemically confirmed gonadotroph adenomas are hormonally silent, accounting almost 64% of all clinically nonfunctioning pituitary adenomas. Whereas clinically functioning gonadotroph adenomas (FGA) are very rare and the exact prevalence is not known. We present the case of a FGA in a premenopausal. A 31-year-old female presented in the ED with oligomenorrhea for 11 months, abdominal pain and distention over the precedi...

ea0094p93 | Neuroendocrinology and Pituitary | SFEBES2023

The clinical course of pituitary metastases: illustrations from clinical cases

Shaikh Sheeba , Iqbal Zohaib , Garcez kate , Waddell Tom , Hoong Ho Jan , Adam Safwaan

Pituitary metastases are reportedly uncommon. Here we report two cases illustrating metastases responding to systemic anticancer therapy (SACT). A 49-year-old woman with metastatic renal cell carcinoma treated with combination ipilimumab and nivolumab immunotherapy was referred for hypocortisolaemia (morning cortisol 74 nmol/l). Biochemical screening revealed an adrenocorticotropic hormone of 16ng/l (0-46), thyroid-stimulating-hormone 0.1mU/l (0.55-4.78), free thyroxine 7 pmol...

ea0094p94 | Neuroendocrinology and Pituitary | SFEBES2023

Effectiveness of Dopamine Agonists in managing Non-Functioning Pituitary Adenomas- a United Kingdom single centre retrospective review

Tam Trevor , Soong Elaine , Saada Louis , Marcus Hani , Dorward Neil , Swords Francesca , Dhatariya Ketan , Ahluwalia Rupa

Background: While dopamine agonists (DAs) are used for managing residual/recurrent non-functioning pituitary adenomas (NFPAs), guidance on patient selection, drug dosing, follow-up imaging and response criteria is lacking.Methods: Retrospective review of NFPAs treated with DAs at a U.K single centre. 14 patients on Cabergoline (November 2011-2022) were identified. Radiological response was based on 2 follow-up (FU) scans...

ea0094p95 | Neuroendocrinology and Pituitary | SFEBES2023

Pituitary apoplexy with a twist

Elamin Aisha , Pallai Shillo , Macinerney Ruth , Khalifa Mai , Went Richard

Introduction: Multiple myeloma (MM) is a haematological disorder characterised by an aberrant rise in monoclonal paraprotein. Intrasellar plasmacytomas can be infrequent MM manifestations. They are challenging to diagnose and frequently mimic pituitary adenomas; however rarely present with pituitary apoplexy. We describe a patient with pituitary apoplexy-like symptoms, subsequently diagnosed with MM, whose intrasellar mass entirely resolved after chemotherapy....

ea0094p96 | Neuroendocrinology and Pituitary | SFEBES2023

A first report of pituitary Neuro-Endocrine-Tumour in a young patient with Coffin-Siris syndrome. Is there a link between the ARID1B c.6157dup gene and pituitary tumourigenesis?

Macfarlane James , Lin Nyan , Serban Laura , Sennik Devesh , Ping Jen Jian , Mes Steven , Dean Andrew , Koulouri Olympia , Donelly Neil , Mannion Richard , Gurnell Mark , Panteliou Eleftheria

A 19-year-old gentleman, with Coffin-Siris-Syndrome(CSS)(ARID1B:c.6157dup gene-mutation), was referred to our endocrinology clinic, with rapid weight-gain and recent onset of Type-2-Diabetes. He was of short stature, he had central-adiposity, facial plethora, proximal myopathy and gynaecomastia. Endocrine testing revealed ACTH:61ng/l, Cortisol:772nmol/l, Total-Testosterone:2.8nmol/l, FSH:6.3U/l, LH:2.2U/l, Prolactin:87mU/l, IGF-1:61ug/l, TSH:0.18mU/l, T4:10.3 pmol/l, HbA1C:84m...

ea0094p97 | Neuroendocrinology and Pituitary | SFEBES2023

“The changing colours” –cabergoline induced raynauds phenomenon- a rare clinical presentation

Zafar Sadia , Keen Fred , Roy Chowdhury Sharmistha

Introduction: Prevalence of prolactinoma is approximately 10/100,000 (men) and 30/100,000 (women) and dopamine agonists remain pharmacological treatment of choice. Cabergoline, an effective dopamine agonist, is preferred due to better tolerability withhigher efficacy in lowering prolactin and reducing tumour size in comparison with bromocriptine. Digital vasospasm, known adverse effect of Bromocriptineis mediated by activation of α1 adrenergic receptors. ...

ea0094p98 | Neuroendocrinology and Pituitary | SFEBES2023

Use of metoclopramide to induce lactation in a post-partum female with panhypopituitarism

Lonergan Eibhlin , Kennedy Ashling , Yi Joyce Tan Lok , O'Halloran Domhnall

Lactation is under the control of the anterior and posterior pituitary via prolactin and oxytocin release. A number of galactogogues, including dopamine antagonists, have been described and used with success in lactation induction. To date, there are no reports in the literature of their use in patients with panhypopituitarism. We present the case of a forty-year-old female known to endocrinology services with a background of anterior panhypopituitarism and AVP deficiency asso...

ea0094p99 | Neuroendocrinology and Pituitary | SFEBES2023

Spinal epidural lipomatosis: A rare complication of Cushing’s disease

Bhagi Ridhi , Zafar Sadia , Boam Alicia , Cozma Lawrence , RoyChowdhury Sharmistha

Background: Cushing’s syndrome is rare (1.8-3.2 cases/million population)1, with Cushing’s disease (CD) accounting >70%. We seek to highlight a rare complication, spinal epidural lipomatosis (SEL), rare cause of spinal compression (prevalence-2.5%2), commonly related to exogenous steroid use with 3 reported cases secondary to CD3,4,5.Case: 36-years old man, background asthma and alcohol excess presented wit...

ea0094p100 | Neuroendocrinology and Pituitary | SFEBES2023

Ipilimumab associated hypophysitis and painless thyroiditis: case report

Soare Iulia , Sirbu Anca , Martin Sorina , Fica Simona

Introduction: Ipilimumab is an efficient medication used for the management of melanoma. However, it has been associated with endocrine dysfunctions such as hypophysitis, thyroid disorders (hypo- or hyperthyroidism), and adrenal insufficiency.Case report: We report the case of a 65-year-old male diagnosed with melanoma (Clark V). In 2022, he was operated and received treatment with ipilimumab 3 mg/kg. Three weeks after t...

ea0094p101 | Neuroendocrinology and Pituitary | SFEBES2023

Severe hyponatremia in a 46-year-old female with pituitary stalk duplication and empty sella internal medicine, endocrine department

Boharoon Hessa , AlKhyeli Fatima , Almarzouqi Abdulla , Athar Syed

Introduction: pituitary duplication is a rare congenital malformation. It has been mainly reported in the pediatric and neonatal population with few reported cases in the adult population. In this case we will be discussing the presentation of an adult female patient with pituitary stalk duplication and empty Sella causing hyponatremia.Case Presentation: A 46-year-old female presented with severe euvolemic hyponatremia. ...

ea0094p102 | Neuroendocrinology and Pituitary | SFEBES2023

Macroprolactinoma management during pregnancy

Morrison Amy , Ahsan Masato , Bremner Emma , Todd Diane , Levy Miles

Case: This 23-year-old lady initially presented in 2013 with headaches, galactorrhoea and secondary amenorrhoea. Visual fields were normal to confrontation. Prolactin levels were elevated at 3028miu/l. MRI pituitary revealed a 14x13x15mm adenoma pushing the pituitary stalk posteriorly, and compressing the left side of the optic chiasm.Initial Management: Cabergoline was commenced (250mg twice weekly), with good clinical ...

ea0094p103 | Neuroendocrinology and Pituitary | SFEBES2023

ACTH as a tumour marker in Cushing Disease following surgery

Costache Outas Mariana

Silent corticotroph adenomas are a distinctive subgroup of nonfunctioning pituitary tumours without biochemical or clinical evidence of Cushing’s disease. They are diagnosed after surgery by positive immunostaining for ACTH. They are usually macroadenomas with more aggressive behaviour. On rare occasions, they transform into active Cushing’s disease, with elevated serum ACTH levels. I report a case of a 44 years old lady I first examined in the postoperative neurosur...

ea0094p104 | Neuroendocrinology and Pituitary | SFEBES2023

Ectopic posterior pituitary in an adult with stalk interruption hypogonadotrophic hypogonadism and hyperprolactinaemia

Tellier Genevieve , Berkeley Rhiannon , Wood Ffion , Searell Catrin , Wilton Anthony

Ectopic posterior pituitary is a rare congenital pituitary anatomical defect of complex inheritance resulting in heterogeneous clinical and radiological phenotypes. Presentation is primarily in paediatric patients with growth and development effects. We present a rare adult presentation patient. A 33 year old male presented with low libido and paucity of facial hair. Previous medical history was limited to a left undescended testis. He took no regular medications, anabolics or...

ea0094p105 | Neuroendocrinology and Pituitary | SFEBES2023

Arginine vasopressin deficiency (central diabetes insipidus) in a case of suprasellar germinoma: Is it reversible? - Case report

Alshamsi Shamma , Amin Anjali , Meeran Karim

Background: Arginine Vasopressin Deficiency [AVP-D] can occur as consequence of any abnormality or injury at one or more of the sites involved in the Antidiuretic hormone [ADH] secretion. AVP-D is one of the presenting features of suprasellar lesions with panhypopituitrism. The natural course of the disease differs based on the underlying aetiology. It is likely to be transient post-operatively. Idiopathic DI is usually permanent however DI can be reversible w...

ea0094p106 | Neuroendocrinology and Pituitary | SFEBES2023

A case report of relapse of non-Hodgkin lymphoma presented with diabetes insipidus

Abdelgadir Musa Abdelmajid , Pawlak Tadeusz , Santhosh Abraham , Uddin Mohammad

Introduction: There are many causes of central diabetes insipidus including trauma, drugs, metastatic tumor, lymphoma, leukemia, inflammation, virus infection and gene mutation. They’re very few cases in England reported as pituitary involvement of NHL [no-Hodgkin lymphoma] Approximately about 31 cases were reported in the literature as NHL of the pituitary as in Pub medicine, however in these series of cases the most common presentation among them was ce...

ea0094p231 | Neuroendocrinology and Pituitary | SFEBES2023

Analyses of the effects of adrenomedullin on the gonadotrophin-releasing hormone pulse generator and luteinising hormone pulses

Oshimo Yukina , Sato Marimo , Kondo Yuri , Hayashi Natsuho , Cui Wenhao , Nakamura Sho , Matsuyama Shuichi , Ohkura Satoshi , Magata Fumie , Matsuda Fuko

The pulse mode of gonadotrophin-releasing hormone (GnRH) release from the hypothalamus and following luteinising hormone (LH) pulses from the pituitary induce follicular development in female animals. Kisspeptin neurons in the hypothalamic arcuate nucleus (ARC) are suggested to be the GnRH pulse generator. Adrenomedullin (AM) is a secretory peptide expressed in various tissues, including the hypothalamic paraventricular nucleus, but its functions in the central regulation of r...

ea0094p232 | Neuroendocrinology and Pituitary | SFEBES2023

The relationship between serum oxytocin and measures of quality of life in hypopituitary patients – a cross sectional case control study

Mihai Gabriela , O' Shea Triona , Zarif Nadia , Glynn Nigel , Murphy Kevin , Druce Maralyn

Introduction: Patients with hypopituitarism often report poor quality of life (QoL) despite adequate hormonal replacement therapy. Oxytocin, a peptide hormone produced in the hypothalamus and released by the posterior pituitary, has been known for its role in social and emotional behaviour. Our aim was to investigate the relationship between oxytocin and QoL domains in patients with hypopituitarism under optimal hormonal replacement therapy.<p class="abste...

ea0094p233 | Neuroendocrinology and Pituitary | SFEBES2023

Characterisation of the Impact of Joint Pain on Patients with Acromegaly

Hebden Sophie , Safdar Nawaz , Heague Megan , Lynch Julie , Mclaren David , Tresoldi Alberto , Lithgow Kirstie , Urwyler Sandrine , Akbar Shahzad , McLoughlin Katie , Kearney Tara , M Drake William , Sathyapalan Thozhukat , Orme Steve , E Higham Claire , Karavitaki Niki , Kyriakakis Nikolaos , Murray Robert

Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor (IGF-1) secretion. Arthropathy is a leading cause of morbidity and impaired quality of life in acromegalic patients, often persisting despite therapeutic interventions and biochemical control. This cross-sectional study aimed to characterise the extent and impact of arthropathy in terms of pain and functional impairment. Validated questionnaires, including DASH (Disabilities of the Arm, Should...

ea0094p234 | Neuroendocrinology and Pituitary | SFEBES2023

The utility of routine fasting gut hormone assessment in asymptomatic individuals with Multiple Endocrine Neoplasia Type 1 (MEN1)

Muhammad Tahir Chohan Dr , Chris Boot Dr , Anna L Mitchell Dr

Background: Secretory pancreatic neuroendocrine tumours (PanNET) are common in MEN1. The MEN1 Clinical Practice guideline (Thakker, 2012) recommends annual assessment of fasting gut hormones (FGH) with annual pancreatic imaging for routine NET surveillance in MEN1.Study aim: To determine whether FGH (gastrin, glucagon, somatostatin, pancreatic polypeptide, VIP, insulin, chromogranin-A) in a cohort of asymptomatic individ...

ea0094p235 | Neuroendocrinology and Pituitary | SFEBES2023

Short chain fatty acid ameliorates hypothalamic apoptosis in a rat model of polycystic ovarian syndrome via modulation of gamma-aminobutyric acid

Agan Shalom , Areloegbe Stephanie , Bashir Al-Amin , Olaniyi Kehinde

Background of Study: Polycystic ovarian syndrome (PCOS) is an endocrine disorder, contributing to increased neurodegenerative disorders including hypothalamic disturbance. Short chain fatty acid (SCFA) has been reported to regulate metabolic health. However, its therapeutic nature in hypothalamic dysfunction, especially in PCOS individuals is unknown. This study hypothesized that SCFA reverses hypothalamic injury and its related abnormalities in experimentally...

ea0094p236 | Neuroendocrinology and Pituitary | SFEBES2023

Desmopressin prescribing in Arginine Vasopressin (AVP) Deficiency at University Hospitals of Leicester: a further case for a name change from Diabetes Insipidus

Morrison Amy , Fleming Suzannah , Goldney Jonathan , Levy Miles , Patel Tabassum

Background: Cranial diabetes insipidus (DI) is characterised by the inability to produce ADH (antidiuretic hormone) also known as AVP (arginine vasopressin) resulting in uncontrolled diuresis. Desmopressin is a synthetic form of AVP used to treat this. Treatment errors can lead to dehydration and hypernatremia which can be life-threatening. In view of recent literature suggesting current concerns with Desmopressin administration worldwide, Diabetes Insipidus i...

ea0094p237 | Neuroendocrinology and Pituitary | SFEBES2023

A post-operative fluid restriction protocol to reduce the incidence of delayed hyponatraemia following trans-sphenoidal pituitary surgery

Shyamasunder Asha Hesarghatta , Joseph Aneez , Kapoor Nitin , Paul Thomas , Thomas Nihal , Jebasingh Felix , Elizabeth Cherian Kripa , Rajan Remya , Prabhu Krishna , Chacko Ari , Christudoss Pamela , Jose Arun , Rebekah Grace

Delayed hyponatraemia(DH) is a well-known complication following trans-sphenoidal pituitary surgery (TSS), varying in incidence from 9–36% and occurs between post-operative days(POD) 4 to 14. Various studies have demonstrated that post-operative fluid restriction after TSS reduces the incidence of DH.Objective: to assess whether a fluid restriction protocol from POD5 to POD14 following TSS reduces the incidence of post-operative DH ...

ea0094p238 | Neuroendocrinology and Pituitary | SFEBES2023

Is the cannulated prolactin an useful test in evaluation of hyperprolactinemia?

Chirila-Berbentea Veronica , Carroll-Moriarty Leigh , Bhattacharya Beas

Background: Hyperprolactinemia is one of the most common endocrine disorders of the hypothalamic-pituitary axis. It is difficult to differentiate between stress induced hyperprolactinemia and true hyperprolactinaemia and may result in patients having unnecessary imaging.Methods: We have collected data for 46 patients who had a cannulated prolactin test between January 2017 and June 2023 in the Royal United Hospital of Ba...

ea0094p239 | Neuroendocrinology and Pituitary | SFEBES2023

An aggressive prolactinoma with orbital involvement and excellent response to treatment with temozolamide. A case report and systematic literature review

Khalilova Samira , Gonzales Christine , E Drakou Eftychia , K Dimitriadis Georgios

A proportion of prolactinomas exhibit aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment, and recurrence potential) and few may exhibit metastasizing potential (carcinomas). We present an uncommon case of intra-orbital spread from a large infiltrative prolactinoma, with excellent response to temozolomide and a systematic review of the literature. A 55y.o male patient presented with generalized weakness and hyponatraemia. Fu...

ea0094p240 | Neuroendocrinology and Pituitary | SFEBES2023

Psychiatric side effects of cabergoline treatment of hyperprolactinaemia: risk factors and prevalence of patient counselling and monitoring

Child Louisa , Martin Niamh

Background: There is increasing evidence that dopamine agonists used to treat hyperprolactinaemia may cause psychiatric side effects. Male patients have been identified to be at increased risk. This study aimed to establish the incidence of cabergoline-induced psychiatric side effects, potential risk factors for their development and to determine the prevalence of counselling and monitoring for these side effects.Methods:</strong...

ea0094p241 | Neuroendocrinology and Pituitary | SFEBES2023

Assessing healthcare professionals’ knowledge on Cranial Diabetes Insipidus (CDI) and Recognition of the Proposed New Name of Arginine Vasopressin Deficiency(AVPD)

Naing Htoon Kyaw , Turki Mohanad , Munir Alia

Background: Cranial Diabetes insipidus (CDI) is a rare condition but is potentially life-threatening if there is a delay or omission of desmopressin. Recent patient safety alerts highlighted the need to raise awareness to avoid mortality and morbidity. The baseline knowledge of the health care professional (HCPs) is very important to avoid deleterious outcomes.Aim: Qualitative survey to determine the baseline knowledge a...

ea0094p242 | Neuroendocrinology and Pituitary | SFEBES2023

Uncontrolled primary hypothyroidism causing pituitary hyperplasia and mimicking pituitary adenoma

Hamilton Amanda , Panicker Janki

Pituitary hyperplasia secondary to primary hypothyroidism (PHPH) is a consequence of long term untreated or uncontrolled primary hypothyroidism. The proliferation of thyrotrophs in the pituitary gland, due to the lack of negative feedback on the hypothalamus from low circulating thyroid hormone levels, causes elevated thyroid stimulating hormone (TSH) levels. Hyperprolactinaemia can also be present due to the stimulatory effect of TSH on lactotrophs. Pituitary hyperplasia caus...

ea0094p243 | Neuroendocrinology and Pituitary | SFEBES2023

A rare case of phaeochromocytoma secondary to Phosphatase and Tensin Homolog (PTEN) mutation

Narula Kavita , Lazarus Katharine , Sharma Bhavna , Yang Wei , Alexiadou Kleopatra , Avari Parizad , Hui Elaine , Desouza Bianca , Tan Tricia

A 65-year-old female with PTEN Hamartoma Tumour Syndrome, Follicular thyroid carcinoma, and Endometrial Carcinoma, presented at a tertiary centre due to an asymptomatic adrenal lesion. Previous genetic testing for phaeochromocytoma and paraganglioma in 2020 showed no pathogenic variants in multiple genes (FH, MAX, MEN1, SDHx, SDHAF2, TMEM127, VHL, RET gene). Recent imaging revealed a 9 cm left supra-renal lesion that had been gradually increasing in size since 2010. Plasma nor...

ea0094p244 | Neuroendocrinology and Pituitary | SFEBES2023

Co-occurrence of neurofibromatosis type 1 and pituitary rathke cleft cyst

Tabasum Maria , Ahmed Nabeel , Harris Laura , Clarke-Burns Rosanna , Brotherton Sophie , Srinivas-Shankar Upendram

Introduction: The most common sellar and suprasellar lesions are pituitary adenomas, craniopharyngiomas and benign cysts. Rathke’s cleft cyst (RCC) is a benign developmental sellar or suprasellar cystic lesion, which is rarely symptomatic.Case HistoryWe present the case history of 21-year-old woman with a suprasellar RCC, causing early optic chiasmal compression and associated with hyperprolactinemia. Past medical history included neurofibromatosis type 1...

ea0094p245 | Neuroendocrinology and Pituitary | SFEBES2023

A challenging case of recurrent cushings disease

Minhas Raisa , Vainieri Erika , Mitchell Catherine , Ling Yong , Tarigopula Giridhar , Wernig Florian , Alansari Mustafa

A 45-year-old female developed clinical and biochemical recurrent Cushings’ Disease 2.5 years after transsphenoidal hypophysectomy for 2cm pituitary macroadenoma. Past medical history included Type 2 Diabetes mellitus, asthma, hypertension, grade 3 obesity, dyslipidaemia, depression and sleep apnoea. MRI showed residual pituitary tissue with left sphenoid sinus extension. MDT advised repeat transphenoidal surgery over radiotherapy due to presence of a clearly visible surg...

ea0094p246 | Neuroendocrinology and Pituitary | SFEBES2023

Assessing growth hormone replacement practice in patients with hypopituitarism in queen elizabeth hospital birmingham

Sakthivel Pavithra , Wong Anson , Criseno Sherwin , Toogood Andrew

Background: In the UK, adults with growth hormone deficiency (GHD) are treated with recombinant Growth Hormone (GH) therapy according to NICE guidelines (TA64). Provided that patients show an initial improvement in their quality-of-life score, assessed using the Quality-of-Life Assessment of GHD in Adults (Qol-AGHDA) questionnaire, they can continue with their GH treatment long-term. However, in clinical practice, many patients are observed to discontinue GH r...

ea0094p247 | Neuroendocrinology and Pituitary | SFEBES2023

Primary ileal carcinoid presenting with metastatic ovarian tumours and florid carcinoid syndrome: a multidisciplinary care challenge

S Jayraj Aarthi , Rajanbabu Anupama , Hackett Rhiannon , Ali Rashid Razan , Nag Sath

Introduction: Ovarian metastasis from neuroendocrine tumours is rare with < 80 reported cases. We describe a case of bilateral ovarian metastases from a primary ileal carcinoid tumour managed with somatostatin receptor agonist (SSA) therapy and surgery.Case report: A 68-year-old lady presented with abdominal pain, distension, and episodic facial flushing. Echocardiography done to investigate left bundle branch block ...

ea0094p248 | Neuroendocrinology and Pituitary | SFEBES2023

Hypophysitis: a case report on how multidisciplinary approach aids the diagnosis and management of a rare pituitary disease with nonspecific presentations

Yadanar Kyaw Khin , Thant Lwin Min , Ali Hisham

Introduction: Hypophysitis is the inflammation of the pituitary gland, characterised by hypopituitarism and pituitary enlargement. It can occur as primary (commonly lymphocytic, granulomatous or xanthomatous) or secondary to systemic disease, immunotherapy or sella-based pathologies.Case Presentation: A 30-year-old female was admitted to hospital with headache, fatigue, low mood and blurred vision, 3 months after having ...

ea0094p249 | Neuroendocrinology and Pituitary | SFEBES2023

Beyond the run: Loperamide’s toll on the pituitary gland

Shah Preet , Ward Emma

A 76-year-old lady with a background of Crohn’s disease (ileostomy in 1991) was referred to endocrinology in March 2022. Her 9-am cortisol level was <50 nmol/l, with a sodium of 130 mmol/l. These were done as she reported tiredness, lethargy and dizziness since November 2021. She had also lost 7 lb of weight. No evidence of hyperpigmentation. She had then been empirically started on hydrocortisone (10 mg-morning, 5 mg-afternoon and 5 mg-evening) pending evaluation of ...

ea0094p250 | Neuroendocrinology and Pituitary | SFEBES2023

Hypophysitis secondary to monoclonal antibody treatment

Anand Viswesh , T Srinivasan Balasubramanian

Background: Immunotherapy has become one of the standard interventions to treat various malignancies and auto-immune conditions with favourable responses to the treatment. However, the immune related adverse events of these medications are diverse which may include a variety of endocrinopathies, like Hypo cortisol, Hypophysitis, hypo and hyperthyroid states.Case report: A 62 year old female with a background of Metastati...

ea0094p251 | Neuroendocrinology and Pituitary | SFEBES2023

Severe arginine vasopressin resistance (nephrogenic diabetes insipidus) secondary to lithium requiring intensive care admission

Keen Fred , Hamdan Khaliq , Beckett Samuel , Smeeton Fiona

Arginine vasopressin resistance (AVP-R) (previously termed nephrogenic diabetes insipidus) is well known to be associated with lithium treatment. However, cases are usually mild and patients can almost always compensate for their polyuria with excessive fluid intake. We present the case of a moribund patient who required intensive care admission secondary to AVP-R, developing hypernatraemia to 183mmol/l and serum osmolality of 394mmol/kg. A 68 year old gentleman, on lithium tr...

ea0094p252 | Neuroendocrinology and Pituitary | SFEBES2023

A rare presentation of cushing’s disease with aortic dissection- a case report

Pambinezhut Kunjumohaned Fathima , Idampitiya Chandima , Ranathunga Ishara

Key words- Cushing’ Disease, Aortic DissectionBackground: Cushing’s syndrome is a rare endocrine disorder. It is frequently presented with obesity, type 2 diabetes, or hypertension with an increased cardiovascular risk. The association of Cushing’s syndrome with aortic dissection is rare. We report a young man who presented with hypertensive emergency and aortic dissection. He was later found to have Cushing’s disease...

ea0094p253 | Neuroendocrinology and Pituitary | SFEBES2023

Young male presented with primary hyperparathyroidism secondary to Multiple Endocrine Neoplasia type 1 syndrome

Salah Uddin Mohammad , Mohammed Kamrudeen , Deshmukh Harshal , Taqi Muhammad , Akbar Shahzad

MEN1 is a rare hereditary tumor syndrome characterized by a predisposition to a multitude of endocrine neoplasms primarily of parathyroid, enteropancreatic, and anterior pituitary origin and non endocrine tumor. Here we will discuss a case of 36 yrs. old male who was referred for high calcium on routine blood test. Subsequent investigations confirmed primary hyperparathyroidism. His serum calcium level was 2.71, PTH 7.5 Pmol/l, and vitamin D 57.4 nmol/l on presentation and was...

ea0094p254 | Neuroendocrinology and Pituitary | SFEBES2023

Oral contraceptive pill (yasmin®) can partially suppress ACTH secretion in addison’s disease

Gluchowska Monika , Lewinski Andrzej , Lewandowski Krzysztof

Background: ACTH concentrations remain typically elevated in patients with Addison’s disease. We present a case of an extremely potent oral contraceptive pill (OCP) induced increase in total cortisol resulting in inhibition of ACTH secretion that was normalized on OCP withdrawal.Case Presentation: A 20-year old female was diagnosed with Addison’s disease [cortisol 1.59 µg/dl, ACTH>500 pg/ml (0-65)] and...

ea0094p255 | Neuroendocrinology and Pituitary | SFEBES2023

A “never” event case of hyponatraemia

Rhiannon Berkeley , Tellier Genevieve , Searell Catrin , Wood Ffion , Wilton Anthony

An NHS Patient Safety Alert in 2016 warned “Risk of severe harm or death when desmopressin (DDAVP) is omitted or delayed in patients with cranial diabetes insipidus”. Endocrinologists added “It (DDAVP) needs to be continued in all situations with the assistance of endocrine teams”.Case report: A 63 year old male was referred with a sodium of 116 mmol/l following a re-do hip replacement 2 weeks earlier. A progressive d...

ea0094p256 | Neuroendocrinology and Pituitary | SFEBES2023

Acromegaly with normal phenotype?

Rajpar Hiba , QURESHI Sheharyar

Introduction: More than 95% of cases of Acromegaly are caused by pituitary adenomas that present with insidious onset of symptoms due to local mass effects or due to excess of GH/IGF-1. It is often diagnosed late and results in high morbidity and mortality.Case: We present a case of a woman in her fifties with atypical presentation of acromegaly with a left sided headache for 2 years with no associated visual symptoms an...

ea0094p257 | Neuroendocrinology and Pituitary | SFEBES2023

A complex case of Acromegaly, resistant to treatment & discovered during pregnancy; A regional, collaborative approach

May Caroline , Kinton Rebecca

Background: Acromegaly is a rare Endocrine condition caused by excessive secretion of growth hormone; in 2022, there were approximately 3500 people with a known diagnosis in the UK. Patients with Acromegaly can achieve successful remission of the disease with medical therapy, pituitary surgery and radiotherapy (sometimes a single treatment, sometimes combination). However, these treatment options have associated risks, including side effects, late effects of r...

ea0094p357 | Neuroendocrinology and Pituitary | SFEBES2023

An endocrine cause of diabetes remission

Khanam Amina , Surendran Aarthi

29 year old African lady with a background of PCOS and type 2 diabetes, who was under the care of preconception clinic, presented to A&E with sudden onset headache associated with spontaneous closure of right eyelid. CT brain was suggestive of pituitary fossa lesion and pituitary MRI revealed pituitary necrosis. She was diagnosed with pituitary apoplexy and was commenced on appropriate hormone replacement. Examination revealed right complete third nerve palsy and reduced v...

ea0094p358 | Neuroendocrinology and Pituitary | SFEBES2023

Copy number variation (CNV) in self-limited delayed puberty (SLDP)

Al-Sayed Yasmin

Self-limited delayed puberty (SLDP) is characterized by an onset of puberty that is more than 2-2.5 standard deviations later than the population mean age and is often familial with strong genetic determinants. The reproductive axis is regulated by gonadotropin-releasing hormone (GnRH), which plays a crucial role in initiating puberty and maintaining fertility through its pulsatile secretion. Disruption in GnRH neuron development or hypothalamic function can lead to delayed pu...

ea0094p359 | Neuroendocrinology and Pituitary | SFEBES2023

Prescription profile of narrow therapeutic index medications used in pediatric endocrinology

Acuna Hernandez Marylin , Caro Uribe Patricia , Portilla Pinzon Alfredo , Machado Duque Manuel , Orozco Escobar Andrea , Casanova Libreros Rosangela

Introduction: According to the FDA, narrow therapeutic index (NTI) medications are those in which small differences in dosage orblood concentration can lead to serious therapeutic failures and/or adverse reactions that can endanger the patient’s life or result inpersistent or significant disability or incapacity. A literature not have studies about used this medication use in endocrinology pediatric population. OBJECTIVE: Establish the prescription profil...

ea0094p360 | Neuroendocrinology and Pituitary | SFEBES2023

A 3D neurosteroids atlas of mouse brian using mass spectrometry imaging

Khan Shazia , Yutuc Eylan , L.W. Yau Joyce , Wang Yuqin , J Griffiths William , Andrew Ruth

Neurosteroids are synthesized locally within the central nervous system and play essential roles in modulating neuronal activity and various brain functions. They can have a wide range of effects, including anxiolytic, sedative, analgesic, and neuroprotective actions. Understanding their distribution in the brain and how they interact with neurotransmitter systems is of significant interest to researchers studying brain function and related disorders. We aim to construct a 3D ...

ea0094p361 | Neuroendocrinology and Pituitary | SFEBES2023

Unusual presentation of suprasellar lesion with adrenal crisis/pan-hypopituitarism but raised tsh

Ali Mudassir , Mada Srikanth

A 44 years old lady with history of suspected psychogenic polydipsia (2021), presented with acute on chronic abdomen pain. She complained of lethargy, intermittent vomiting, abdomen pain, weight loss (four stones) over last six months associated with confusion and visual hallucination since two weeks. She mentioned feeling always thirsty and drinks around 4-5 litres of water per day. Her blood pressure was 87/61 mmHg, heart rate 74/min and U&Es were normal (serum sodium 14...

ea0094p362 | Neuroendocrinology and Pituitary | SFEBES2023

Pituitary adenomas- a retrospective review of a health board’s experience

Bahl Suhani , Obuobie Kofi

Background: Pituitary adenomas are broadly classified based on size (microadenomas and macroadenomas) and functionality. While their management has established national and international guidelines based on these two classifications, we aim to evaluate the same in a post-pandemic era, when health care resources are already stretched and have a significant backlog to deal with.Aim: To carry out a retrospective analysis of...

ea0094p363 | Neuroendocrinology and Pituitary | SFEBES2023

Hindering the progression of cardiac fibrosis in acromegaly – the role of somatostatin receptor ligands

Sanpawithayakul Kanokporn , Mistry Anisha , Rai Ashutosh , Funge Gregory , Sebastian Sonia , Solomou Antonia , Lillina Vignola Maria , Gaston-Massuet Carles , Tinker Andrew , Begalli Federica , Korbonits Marta

Introduction: Acromegaly links to cardiomyopathy and potential cardiac failure, if untreated. Mechanisms involved in acromegalic cardiomyopathy are incompletely understood. We investigated the effects of growth hormone (GH) excess and somatostatin receptor ligands (SRLs) on cardiac fibrosis using an acromegalic mouse model with pituitary-specific deletion of the Aip gene coding aryl hydrocarbon receptor interacting protein (AipFlox/Flox;Hesx1<su...

ea0094p364 | Neuroendocrinology and Pituitary | SFEBES2023

Audit of compliance with NICE TA64 on prescribing growth hormone treatment in adults at the queen elizabeth hospital, birmingham

Tarr Charlotte , Anderson Jennifer , Criseno Sherwin

Adult growth hormone deficiency (AGHD) is a metabolic syndrome characterised by osteoporosis, increased visceral fat, adverse lipid profiles, decreased muscle mass and reduced energy levels. As such, it is associated with reduced quality of life (QoL) and increased mortality from cardiovascular disease. Synthetic growth hormone (GH) can be given to replace natural GH; however, treatment is costly at around £3350 per patient per year and could cause side effects including ...

ea0094p365 | Neuroendocrinology and Pituitary | SFEBES2023

Suboptimal treatment of acromegaly potentially leading to onset and progression of B cell lymphoma

Iacuaniello Davide , Majeed Waseem , Pathmanaban Omar , Roncaroli Federico , Kearney Tara

Acromegaly is a rare endocrine disorder mostly caused by a growth hormone (GH)-secreting pituitary adenoma. The aim of treatment is to normalize GH/IGF1 levels to limit disease burden. Growth hormone hypersecretion is associated with an increased cancer risk; cases of Acromegaly complicated by lymphoma have been reported. We share a clinical case characterized by suboptimal treatment, potentially leading to advancing orbital lymphoma. This 49-year-old man was diagnosed with Ac...

ea0094p366 | Neuroendocrinology and Pituitary | SFEBES2023

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

Whitelaw Ben , Gilbert Jackie , Ling Chuah Ling , Crane James , Dimitriadis Georgios , Thomas Nick , Barazi Sinan , Maratos Eleni , Shapey Jonathan , Laniba Leah , Lazaro Nila , Gordon Nadia , Al-Salihi Omar , King Andrew , Al-Sarraj Safa , Reisz Zita , Bodi Istvan , Al Busaidi Ayisha , U-King-IM Jean-Marie , Aylwin Simon

Temozolomide has an established role as first line chemotherapy for aggressive pituitary adenoma and carcinoma. There are mixed reports whether the MGMT (methylguanine methyltransferase) and mismatch repair protein (MSH2/6) status of a tumour, assessed by immunohistochemistry (IHC) can predict response to temozolomide. This is the first series to assess combined MGMT and MSH2 status. We analysed a retrospective case series of patients treated with temozolomide at our tertiary ...

ea0094p367 | Neuroendocrinology and Pituitary | SFEBES2023

Multisystem Langerhans cell histiocytosis presenting in adulthood. Don’t forget the mouth!

Harvey Aeysha , Bujanova Jana

Background: Langerhans cell histiocytosis (LCH) is an uncommon myeloproliferative disorder characterised by inflammatory lesions and accumulation of histiocytes leading to the destruction of affected tissues. LCH has a variable presentation and can occur as a single indolent lesion or can affect multiple organs such as the pituitary gland, bones, CNS, liver, lungs, lymph nodes, spleen, skin, heart and gastrointestinal tract. LCH of the pituitary gland most com...

ea0094p368 | Neuroendocrinology and Pituitary | SFEBES2023

Every blood clot has story to tell

Kushe Manish

35-year lady with BMI of 43 was admitted to local hospital after acute shortness of breath. History of Right calf pain and swelling was evident which raised suspicion of VTE with high likelihood of Pulmonary Embolism. Subsequent CT Pulmonary Angiogram confirmed the same with origin of clot from her leg DVT. She had successfully thrombolysis in intensive care as per hospital protocol. Her high body mass index was thought to be risk factor for blood clots. Her periods were regul...

ea0094p369 | Neuroendocrinology and Pituitary | SFEBES2023

The Natural History of Clinically Non-functioning Pituitary Macroadenomas (NFPAs) managed conservatively

Cussen Leanne , Green Deirdre , Griffin Emma , Ahmed Mohammed , Burke Kevin , Farrell Terence , Javadpour Mohsen , Agha Amar

Transsphenoidal surgery is the first-line treatment for non-functioning pituitary macroadenomas (NFPAs) causing pressure symptoms. However, the approach to asymptomatic NFPAs is unclear due to the limited data on their natural progression. This study retrospectively analysed data from patients with NFPAs who underwent conservative management for at least six months. The study screened 175 individuals treated at the National Neurosurgery/Pituitary Centre at Beaumont Hospital be...

ea0094p370 | Neuroendocrinology and Pituitary | SFEBES2023

A retrospective review of new hyperprolactinaemia referrals undergoing MRI pituitary

Pyar Than Yu Kyi , Jose Biju , Joseph Jooly

Hyperprolactinaemia is a common referral reason from primary and secondary care for contrast-enhanced pituitary magnetic resonance imaging (MRI). This retrospective study at University Hospitals of North Midlands, Stoke-on-Trent reviewed the records of new patients referred for pituitary MRI between 1 June 2021 and 31 May 2023 with hyperprolactinaemia as indication. 71 patients were identified. 82% of the cohort were women. Age ranged between 18-87 years; the majority were bet...

ea0094p371 | Neuroendocrinology and Pituitary | SFEBES2023

GnRH neuronal disruption and hypotestosteronemia in COVID-19

Sauve Florent , Nampoothiri Sreekala , Clarke Sophie , Fernandois Daniela , Fernando Ferreira Coelho Caio , Dewisme Julie , G Mills Edouard , Ternier Gaetan , Cotellessa Ludovica , Iglesias Garcia Cristina , Mueller-Fielitz Helge , Lebouvier Thibaud , Perbet Romain , Florent Vincent , Baroncini Marc , Sharif Ariane , Ereno-Orbea June , Mercado-Gomez Maria , Palazon Asis , Mattot Virginie , Pasquier Florence , Catteau-Jonard Sophie , Martinez-Chantar Maria , Hrabovszky Erik , Jourdain Merce , Deplanque Dominique , Morelli Annamaria , Guarnier Giulia , Storme Laurent , Robil Cyril , Trottein Francois , Nogueiras Ruben , Schwaninger Markus , Pigny Pascal , Poissy Julien , Chachlaki Konstantina , Maurage Claude-Alain , Giacobini Paolo , S Dhillo Waljit , Rasika S , Prevot Vincent

Loss of gonadotropin-releasing hormone (GnRH) and cognitive deficits have recently been demonstrated by our group in conditions including Down syndrome and Alzhiemer’s disease. In some patients with COVID-19, olfactory and cognitive alterations persist, and persistent hypotestosteronemia in SARS-CoV-2-infected men could be a consequence of deficient GnRH. To understand whether neuroinvasion of GnRH system by SARS-CoV-2 could explain some post-COVID symptoms and thus resul...

ea0094p372 | Neuroendocrinology and Pituitary | SFEBES2023

An unusual case of Myeloma masquerading as SIADH

SAHAY NIKITA , Srinivasan Venkataramanan , JOHN REGGIE

Introduction: Hyponatremia from SIADH secondary to undiagnosed Myelomas are extremely rare and we present one such case.Clinical case: 63 year old woman with background of MGUS under regular haematology review/ILD/NAFLD/IHD presented with severe constipation on top of weakness, weight loss and tingling in the peripheral extremities. She was euvolemic on admission with Serum Sodium 124mmol/l, Potassium 4.3 mmol/l, Urea 3....

ea0094p373 | Neuroendocrinology and Pituitary | SFEBES2023

A case of mild autonomous cortisol secretion (MACS) to full-blown Cushing Disease

Yin Yin , Rasheed Hira , Ogunko Arthur , Abedo Itopa

A 44 years old lady was reviewed by endocrinology team in January 2020 for weight gain, increased fat deposition around the neck, constant fatigue and decreased libido. She denied usage of exogenous steroids. She was normal BMI, normotensive and did not display signs of Cushing’s syndrome in first visit. Although overnight dexamethasone suppression was failed to suppress: cortisol of 141 nmol/l and ACTH 78 ng/l, Low dose dexamethasone suppression test (LDSST) was adequate...

ea0094p374 | Neuroendocrinology and Pituitary | SFEBES2023

A case of pituitary apoplexy on long term cabergoline for prolactinoma

Ahsan Masato , Mahbub Swapnil Asif , Zaman Sajnin , Macriyiannis Thrasos , Venugopalprabhu Vimal

Pituitary apoplexy is an uncommon, but well recognised clinical syndrome, which usually results from ischaemic or haemorrhagic necrosis of pituitary gland, which is frequently precipitated by an existing pituitary adenoma. Early diagnosis of this condition is essential as prompt management may be life and vision saving. We are highlighting a case of Pituitary apoplexy on long term Cabergoline for Prolactinoma.Case report: A 62 year old l...

ea0094p399 | Neuroendocrinology and Pituitary | SFEBES2023

Paltusotine maintains IGF-1, GH, and symptom control in patients with acromegaly switched from injected octreotide or lanreotide monotherapy: Topline results from PATHFNDR-1, a phase 3, randomized, double-blind, placebo-controlled, multicenter study

R. Gadelha Monica , Casagrande, MD, PhD Alessandra , J. Strasburger MD Christian , Bidlingmaier Martin , Snyder MD Peter , Guitelman MD Mirtha , Boguszewski MD Cesar , Buchfelder MD Michael , Shimon MD Ilan , Raverot MD Gerald , Toth MD Miklos , Mezosi MD Emese , Doknic MD Mirjana , Fan PhD Xiaolin , Clemmons MD David , Keeley PhD Michael , J. Trainer MD Peter , Struthers PhD R. Scott , Krasner MD Alan , M.K. Biller MD Beverly

Paltusotine is a once-daily, oral, selectively-targeted SST2 agonist in development for the treatment of acromegaly. PATHFNDR-1 (NCT04837040) enrolled patients with acromegaly who had an IGF-1 ≤1xULN on a stable (>12 weeks) dose of lanreotide or octreotide. Patients were randomized 1:1 to receive paltusotine 40 mg/day or placebo for 36 weeks. During the first 24 weeks, the paltusotine dose was titrated (range 20-60 mg) based on IGF-1 and tolerance. Dose changes were ...